Purespring Therapeutics develops adeno-associated viral (AAV) gene therapies that directly target the podocyte, a specialised cell implicated in approximately 60% of renal diseases. Its pipeline is led by PS-002 for IgA nephropathy (IgAN) and includes programmes for complement-mediated kidney diseases, a nephrotic syndrome programme, and an undisclosed glomerular kidney disease programme. The company plans to use the new funding to support the pipeline and to initiate a Phase I/II clinical trial for IgAN. Purespring will present its IgAN data publicly for the first time at the American Society of Nephrology (ASN) Kidney Week on October 26 in San Diego. The company is led by CEO Julian Hanak and was founded with backing from Syncona, which remains a founding investor and board participant. The financing is intended to broaden Purespring’s financial scale to advance clinical development and programme execution.

Total raised

$107M

Funding rounds

1

Latest round

Series B

Latest activity

Oct 2024